{
  "context": {
    "rules": [
      "Rule1: If trial alpha has fast-track status, then regulatory approval for trial alpha is not granted.",
      "Rule2: Provided that dosing is complete for trial alpha, patient recruitment for trial alpha has occurred.",
      "Rule3: Whenever analysis is complete for trial alpha, dosing for trial alpha is complete.",
      "Rule4: If phase 1 of trial alpha is complete, then in the absence of FDA oversight for trial alpha, drug X is not approved.",
      "Rule5: Assuming monitoring is complete for trial alpha, Dr. Smith is trained in Good Clinical Practice.",
      "Rule6: If the audit for trial alpha is clean, then it is not the case that a data audit was conducted for trial alpha.",
      "Rule7: In the event that market approval is granted for drug X, regulatory approval for trial alpha is not granted.",
      "Rule8: Either competitor drug Y has an advantage, or if it is not the case that whenever Dr. Smith is certified as a researcher, the protocol was followed in trial alpha, and this leads to the data from trial alpha not being valid, then market approval for drug X results in a patent being filed for drug X.",
      "Rule9: Should a publication be pending for trial alpha, the data from trial alpha is not valid.",
      "Rule10: If phase 2 of trial alpha is complete, then given that there is no FDA oversight for trial alpha, drug X is not approved.",
      "Rule11: Whenever there is media coverage for trial alpha, either a conference presentation was made for trial alpha, or if Dr. Smith is not certified as a researcher implying the protocol was followed in trial alpha, then a publication is pending for trial alpha.",
      "Rule12: Either there is media coverage for trial alpha or there is investor interest in trial alpha.",
      "Rule13: Provided there is investor interest in trial alpha, either a conference presentation was made for trial alpha, or if Dr. Smith is not certified as a researcher implying the protocol was followed in trial alpha, then a publication is pending for trial alpha.",
      "Rule14: Either safety has been established for trial alpha or efficacy has been established for trial alpha.",
      "Rule15: Assuming efficacy has been established for trial alpha, phase 2 of trial alpha is complete.",
      "Rule16: Provided that trial alpha has been terminated, analysis is complete for trial alpha.",
      "Rule17: Should trial alpha be terminated, it is not the case that patient recruitment is complete for trial alpha.",
      "Rule18: Either trial alpha has been terminated, or if safety has been established for trial alpha, then phase 1 of trial alpha is complete.",
      "Rule19: Whenever adverse events occurred in trial alpha, trial alpha is not terminated.",
      "Rule20: Either adverse events occurred in trial alpha or funding was withdrawn from trial alpha.",
      "Rule21: Assuming funding was withdrawn from trial alpha, trial alpha is not terminated.",
      "Rule22: Should Dr. Smith be certified as a researcher, it is not the case that the protocol was followed in trial alpha.",
      "Rule23: Whenever it is not the case that either phase 1 of trial alpha is complete or phase 2 of trial alpha is complete, the protocol was modified for trial alpha.",
      "Rule24: If it is not the case that Dr. Smith is certified as a researcher implying the protocol was followed in trial alpha, then the data from trial alpha is valid.",
      "Rule25: Should it not be the case that Dr. Smith is certified as a researcher implying monitoring is complete for trial alpha, then a data audit was conducted for trial alpha.",
      "Rule26: If it is not the case that Dr. Smith is certified as a researcher implying monitoring is complete for trial alpha, then the audit for trial alpha is clean.",
      "Rule27: Whenever it is not the case that if neither phase 1 of trial alpha is complete nor phase 2 of trial alpha is complete, then trial alpha has been extended, additional funding has been provided for trial alpha.",
      "Rule28: Should it not be the case that if neither phase 1 of trial alpha is complete nor phase 2 of trial alpha is complete, then trial alpha has been extended, it is not the case that additional funding has been provided for trial alpha.",
      "Rule29: Assuming it is not the case that if neither phase 1 of trial alpha is complete nor phase 2 of trial alpha is complete, then it is not the case that the protocol was modified for trial alpha, new endpoints were established for trial alpha.",
      "Rule30: In the event that it is not the case that if neither phase 1 of trial alpha is complete nor phase 2 of trial alpha is complete, then it is not the case that the protocol was modified for trial alpha, it is not the case that new endpoints were established for trial alpha.",
      "Rule31: Provided that it is not the case that if it is not the case that Dr. Smith is certified as a researcher implying the protocol was followed in trial alpha, then the data from trial alpha is not valid, regulatory approval has been granted for trial alpha.",
      "Rule32: If it is not the case that if it is not the case that Dr. Smith is certified as a researcher implying the protocol was followed in trial alpha, then the data from trial alpha is not valid, trial alpha has fast-track status.",
      "Rule33: In the event that it is not the case that if it is not the case that whenever Dr. Smith is certified as a researcher, the protocol was followed in trial alpha, and this leads to the data from trial alpha not being valid, then market approval for drug X results, it is not the case that a patent has been filed for drug X.",
      "Rule34: If there is no FDA oversight for trial alpha, then drug X is approved.",
      "Rule35: Provided there is no FDA oversight for trial alpha, Dr. Smith is certified as a researcher."
    ],
    "facts": [
      "Fact1: It is not the case that trial alpha has been extended.",
      "Fact2: It is not the case that Dr. Smith is trained in Good Clinical Practice.",
      "Fact3: It is not the case that competitor drug Y has an advantage.",
      "Fact4: It is not the case that a conference presentation was made for trial alpha."
    ]
  },
  "question": "There is FDA oversight for trial alpha."
}